Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-21EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…
-
EMA approval · 2026-08-20EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorization of MabThera (rituximab) for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphoc…
-
EMA approval · 2026-08-19EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-19EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG
Authorisation granted in the EU for Xeljanz (tofacitinib) for arthritis and rheumatoid conditions.
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
CLINICAL_TRIALS trial_result · 2026-08-14Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis [Phase 3]
Phase 3 trial comparing oral upadacitinib to subcutaneous adalimumab in adults with moderate-to-severe rheumatoid arthritis has completed.
-
EMA approval · 2026-08-13EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…
-
CLINICAL_TRIALS trial_result · 2026-08-11Clinical Trial Results: Use of Acthar in Rheumatoid Arthritis (RA) Related Flares [Phase 4]
Phase 4 clinical trial results evaluating Acthar for rheumatoid arthritis flares have been completed with results posted.
-
EMA approval · 2026-08-06EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) by Roche Registration GmbH for multiple indications including non-Hodgkin lymphoma, rheumatoid arthritis…
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-08-04EMA Authorised: Leflunomide medac (leflunomide) — medac Gesellschaft für klinische Spezialpräparate mbH
Authorised status for Leflunomide medac (leflunomide) intended for rheumatoid arthritis.
-
EMA approval · 2026-07-30EMA Authorised: Leflunomide ratiopharm (leflunomide) — Ratiopharm GmbH
Authorisation of Leflunomide Ratiopharm (leflunomide) for rheumatoid arthritis in the EU.
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
EMA withdrawal · 2026-07-28EMA Withdrawn: Inflectra (infliximab) — Pfizer Europe MA EEIG
The EMA has withdrawn Inflectra (infliximab) from the market.
-
CLINICAL_TRIALS trial_result · 2026-07-27Clinical Trial Results: Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis [Phase 3]
Long-term extension study assessing safety and efficacy of filgotinib in adults with rheumatoid arthritis (Phase 3) has completed.
-
CLINICAL_TRIALS trial_result · 2026-07-27Clinical Trial Results: Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) [NA]
Feasibility and acceptability results from the PREVAIL trial investigating valued activities in life for rheumatoid arthritis patients; stud…
-
CLINICAL_TRIALS trial_result · 2026-07-24Clinical Trial Update: A Randomized Clinical Trial Evaluating the Efficacy of Clinical Pharmacist Assistance Along With Pharmaceutical and Non-pharmaceutical Therapy in the Early Rheumatoid Arthritis [Phase 2, Phase 3]
A randomized clinical trial evaluating the efficacy of clinical pharmacist assistance along with pharmaceutical and non-pharmaceutical thera…
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
CLINICAL_TRIALS trial_result · 2026-07-20Clinical Trial Results: CD40L Antagonism in Rheumatoid Arthritis (RA) [Phase 2]
Phase 2 trial of a CD40L antagonist in rheumatoid arthritis was terminated with results posted.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-16EMA Authorised: Xeljanz (tofacitinib) — Pfizer Europe MA EEIG
EMA authorises Xeljanz (tofacitinib) for rheumatic arthritis under Pfizer Europe MA EEIG.
-
EMA approval · 2026-07-15EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG
Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…